{"page_content": "ESG Report 2023\nDiscussion, by world region, of management process for  \nensuring quality and patient safety during clinical trials  \nSASB: HC-BP-210A.1\nAgios follows all review and approval procedures required by \napplicable laws and regulations before initiating clinical research. Agios protects patient safety and well-being through appropriate informed consent procedures and Good Clinical Practices. For more information, see Agios\u2019 Code of Business Conduct and Ethics.\nNumber of FDA Sponsor Inspections related to clinical  \ntrial management and pharmacovigilance that resulted  \nin: (1) Voluntary Action Indicated (VAI) and (2) Official  \nAction Indicated (OAI)  \nSASB: HC-BP-210A.2\nNo FDA sponsor inspections in 2022.\nTotal amount of monetary losses as a result of legal proceedings \nassociated with clinical trials in developing countries  \nSASB: HC-BP-210A.3  \nNo monetary losses resulting from legal proceedings in 2022.  \nFor more information, see Agios\u2019 2022 10-K.Safety of Clinical Trial Participants\nCommitted to the Humane  \nTreatment of Animals in Research\nIn early 2022, Agios achieved American Association for Accreditation of \nLaboratory Animal Care (AAALAC) accreditation for our animal research facility. AAALAC is an internationally recognized standard for application of the highest criteria toward animal welfare, care and usage. This accreditation exemplifies our dedication to excellence in animal care, which results in a better environment for animals and higher quality research for patients.\nClive Patience,  \nChief Technical  \nOperations Officer\n15", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 14, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}